Skip to content

menu

Rothwell, Figg, Ernst & Manbeck, P.C. logo
HomeAboutContact
Rothwell Figg's

Biosimilars Law Bulletin

RegulatoryLegalNews

RFEM’s Biosimilars Inter Partes Review (IPR) Dashboard

RF-Generic-Logo-sm
By Nicole Gifford & Benjamin R. Holt on November 14, 2018
Posted in Legal

RFEM’s Biosimilars IPR Dashboard provides current information on IPR proceedings related to proposed biosimilar products.

Tags: abatacept, adalimumab, Avastin®, bevacizumab, Enbrel®, etanercept, Featured, Herceptin®, Humira®, IPR, Legal, Natalizumab, Neulasta®, News, Orencia®, pegfilgrastim, PTAB, Rituxan®, Rituximab, trastuzumab, Tysabri®, USPTO
Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Related Posts
Supreme Court of the United States
Amgen v. Sanofi Case on Enablement of Antibody Genus Claims Will be Heard at the Supreme Court; Cert Denied in Juno v. Kite
November 7, 2022
Prescription Bottles
Declaratory Judgment Jurisdiction Over Skinny Label Applications: In re: Entresto (Sacubitril/Valsartan) Patent Litigation
October 25, 2022
Vaccines and gavel
Tysabri® (natalizumab) Litigation Begins
September 15, 2022

Blog Editors

Photo of E. Anthony FiggE. Anthony Figg
Photo of Joseph A. HyndsJoseph A. HyndsMember
Photo of Jennifer P. NockJennifer P. NockMember
Photo of Aydin H. HarstonAydin H. HarstonMember

About this Blog

Authored and edited by attorneys in Rothwell Figg’s Biologics and Biosimilars Group, Rothwell Figg’s Biosimilars Law Bulletin provides updates, articles, and analyses regarding regulatory issues, legal decisions, and other news related to biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA).

Read More....

Stay Connected

RSS LinkedIn Twitter Facebook
Subscribe to this blog

Topics

Archives

Blog Authors Show/Hide

  • D. Lawson Allen
  • Nicole M. DeAbrantes
  • Kathleen DiNapoli
  • Rachel M. Echols
  • Aydin H. Harston
  • Monica Chin Kitts
  • Malissa Magiera
  • Jennifer P. Nock
  • Andrew J. Storaska
  • Anjali Jenna (AJ) Teigen
  • Vivian Tian
  • Sheena Wang
  • Richard E. Waterman
  • Xiaoban Xin

Recent Posts

  • Amgen v. Sanofi Case on Enablement of Antibody Genus Claims Will be Heard at the Supreme Court; Cert Denied in Juno v. Kite
  • Declaratory Judgment Jurisdiction Over Skinny Label Applications: In re: Entresto (Sacubitril/Valsartan) Patent Litigation
  • Tysabri® (natalizumab) Litigation Begins
  • Coherus Scores First Interchangeable Biosimilar Approval for Lucentis®
  • Senators Urge Regulators to Block and Clear Patent Thickets

Rothwell Figg Blogs

  • Healthcare Marketing Law
  • Privacy Zone
  • PTAB Law Blog
  • RF EMerge
  • Trademark Opposition Lawyer
Rothwell, Figg, Ernst & Manbeck, P.C.
Washington, DC
901 New York Avenue, NW
Suite 900 East
Washington, DC 20001
202.783.6040
BiosimilarsIPeditors@rothwellfigg.com
Boston
10 Post Office Square
Suite 800 South
Boston, MA 02109
617.312.3101
BiosimilarsIPeditors@rothwellfigg.com
New York
80 South Highland Ave
Ossining, NY 10562
914.941.5668
BiosimilarsIPeditors@rothwellfigg.com
RSS LinkedIn Twitter Facebook
Privacy PolicyDisclaimer

About Our Firm

To learn more about our firm and other practice areas, visit www.rothwellfigg.com.

Copyright © 2022, Rothwell, Figg, Ernst & Manbeck, P.C.. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo